

Calithera Biosciences, Inc.  
Form 4  
December 23, 2015

**FORM 4** UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

OMB APPROVAL  
OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Molineaux Christopher  
  
(Last) (First) (Middle)  
  
C/O CALITHERA BIOSCIENCES, INC., 343 OYSTER POINT BLVD. #200

2. Issuer Name and Ticker or Trading Symbol  
Calithera Biosciences, Inc. [CALA]

3. Date of Earliest Transaction (Month/Day/Year)  
12/21/2015

5. Relationship of Reporting Person(s) to Issuer  
  
(Check all applicable)  
  
\_\_\_\_ Director \_\_\_\_\_ 10% Owner  
 Officer (give title below) \_\_\_\_\_ Other (specify below)  
SR. VP, DEVELOPMENT

(Street)  
  
SOUTH SAN FRANCISCO, CA 94080

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
\_\_\_\_ Form filed by More than One Reporting Person

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|-----------------------------------|
|                                 |                                      |  | Code                           | V Amount (A) or (D) Price   |   |  |                                   |
| Common Stock                    | 12/21/2015                           |  | M                              | 5,418 A \$ 0.96   | 34,793 <sup>(1)</sup>   | D  |                                   |
| Common Stock                    | 12/21/2015                           |  | M                              | 4,749 A \$ 2.64   | 39,542 <sup>(1)</sup>   | D  |                                   |
| Common Stock                    |                                      |  |                                |   | 117,962   | I  | By Trust                          |
| Common Stock                    |                                      |  |                                |   | 109,112   | I  | By Spouse                         |

Edgar Filing: Calithera Biosciences, Inc. - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|
|  |  |                                      |  | Code                           | V (A) (D)   | Date Exercisable Expiration Date                         | Title Amount or Number of Shares                              |
| Employee Stock Option (Right to Buy)       | \$ 0.96  | 12/21/2015                           |  | M                              | 5,418   | <u>(2)</u> 05/22/2023                                    | Common Stock 5,418  |
| Employee Stock Option (Right to Buy)       | \$ 2.64  | 12/21/2015                           |  | M                              | 4,749   | <u>(3)</u> 12/16/2023                                    | Common Stock 4,749  |
| Employee Stock Option (Right to Buy)       | \$ 0.48  | 12/21/2015                           |  | M                              | 4,367   | <u>(4)</u> 12/13/2021                                    | Common Stock 4,367  |
| Employee Stock Option (Right to Buy)       | \$ 0.48  | 12/21/2015                           |  | M                              | 5,512   | <u>(5)</u> 06/12/2022                                    | Common Stock 5,512  |
| Employee Stock Option (Right to Buy)       | \$ 0.96  | 12/21/2015                           |  | M                              | 6,306   | <u>(6)</u> 05/22/2023                                    | Common Stock 6,306  |
| Employee Stock Option                      | \$ 2.64  | 12/21/2015                           |  | M                              | 11,640  | <u>(7)</u> 12/16/2023                                    | Common Stock 11,640   |

(Right to Buy)

## Reporting Owners

| Reporting Owner Name / Address   | Relationships |           |                     |       |
|--|---------------|-----------|---------------------|-------|
|  | Director      | 10% Owner | Officer             | Other |
| Molineaux Christopher<br>C/O CALITHERA BIOSCIENCES, INC.<br>343 OYSTER POINT BLVD. #200<br>SOUTH SAN FRANCISCO, CA 94080 |               |           | SR. VP, DEVELOPMENT |       |

## Signatures

/s/William D. Waddill, as  
Attorney-in-Fact

12/23/2015

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
  - \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Includes 2,500 shares acquired under the Company's 2014 Employee Stock Purchase Plan on November 13, 2015.
  - (2) 1/48 of the Option vests in equal monthly installments one month from 05/23/2013. The option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company.
  - (3) 1/48 of the Option vests in equal monthly installments one month from 12/17/2013. The option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company.
  - (4) 1/48 of the Option vests in equal monthly installments one month from 11/07/2011. The option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company.
  - (5) 1/48 of the Option vests in equal monthly installments one month from 03/27/2012. The option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company.
  - (6) 1/48 of the Option vests in equal monthly installments one month from 05/23/2013. The option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company.
  - (7) 1/48 of the Option vests in equal monthly installments one month from 12/17/2013. The option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.